TNP-470 Reduces Glioblastoma Angiogenesis in Three Dimensional GelMA Microwell Platform.
IEEE Trans Nanobioscience
; 15(7): 683-688, 2016 10.
Article
em En
| MEDLINE
| ID: mdl-27542173
ABSTRACT
Tumor angiogenesis is a promising target for cancer treatment, because severing the supply of oxygen and nutrients to tumors halts tumor growth. Unfortunately, many anticancer drugs, including angiogenesis inhibitors, fail in clinical trials, despite showing high efficiency during in vitro and in vivo experiments. This inconsistency from in vitro and in vivo experiments to clinical trials represents a major obstacle in drug development and cancer treatment. Therefore, we set out to demonstrate how our rapid, stable, easy-to-use three-dimensional (3-D) in vitro angiogenesis model can be used to investigate tumor formation and implement drug screening. In this study, we utilized a 3-D in vitro angiogenesis model, based on gelatin methacrylate (GelMA) hydrogel microwells, to mimic the native microenvironment of tumor angiogenesis. Using this model, we were able to quantify the immigration of endothelial cells into a cancer spheroid during the angiogenic process. Next, we tested the anti-angiogenic effect of the angiogenesis inhibitor, TNP-470, on the cancer spheroids in the model. Based on our results, we believe that this novel in vitro system can be widely used for the high-throughput screening of other anti-angiogenic drugs, and could contribute to the development of personalized medicine in the future.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Sesquiterpenos
/
Glioblastoma
/
Inibidores da Angiogênese
/
Cicloexanos
/
Proliferação de Células
/
Modelos Biológicos
/
Neovascularização Patológica
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
IEEE Trans Nanobioscience
Assunto da revista:
BIOTECNOLOGIA
Ano de publicação:
2016
Tipo de documento:
Article